demonstrated that the mammalian SWI/SNF chromatin-remodeling complex contributes to osimertinib resistance in EGFR-mutant lung cancer models by modulating chromatin accessibility—a process that enhances the expression of resistance-associated genes and promotes cancer cell proliferation. Here, EGFR is linked to lung cancer.